Compare OLED & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | IBRX |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | 691 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 8.0B |
| IPO Year | 1996 | 2015 |
| Metric | OLED | IBRX |
|---|---|---|
| Price | $93.63 | $8.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $137.50 | $12.57 |
| AVG Volume (30 Days) | 741.7K | ★ 31.4M |
| Earning Date | 05-19-2026 | 05-18-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | 9.25 | ★ 38.71 |
| EPS | ★ 5.08 | N/A |
| Revenue | ★ $650,611,000.00 | $113,288,000.00 |
| Revenue This Year | $7.43 | $88.57 |
| Revenue Next Year | $10.84 | $146.98 |
| P/E Ratio | $18.61 | ★ N/A |
| Revenue Growth | 0.45 | ★ 668.31 |
| 52 Week Low | $93.03 | $1.83 |
| 52 Week High | $163.20 | $12.43 |
| Indicator | OLED | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.03 | 53.23 |
| Support Level | N/A | $2.27 |
| Resistance Level | $107.90 | $12.43 |
| Average True Range (ATR) | 3.61 | 0.98 |
| MACD | -0.89 | -0.31 |
| Stochastic Oscillator | 4.22 | 14.16 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.